Three newly formed START criteria (the lack of mineralocorticoid receptor antagonists and SGLT-2 inhibitors in heart failure and the lack of osmotic laxatives for chronic constipation) accounted for most of the additional omissions, compared with START v2. Here, NR3C2 is linked to heart failure.